{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "29062040", "DateCompleted": {"Year": "2019", "Month": "07", "Day": "23"}, "DateRevised": {"Year": "2019", "Month": "07", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "10", "Day": "23"}], "Language": ["eng"], "ELocationID": ["13749", "10.1038/s41598-017-13664-x"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "7", "Issue": "1", "PubDate": {"Year": "2017", "Month": "Oct", "Day": "23"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Regiospecific Synthesis of Ring A Fused Withaferin A Isoxazoline Analogues: Induction of Premature Senescence by W-2b in Proliferating Cancer Cells.", "Pagination": {"StartPage": "13749", "MedlinePgn": "13749"}, "Abstract": {"AbstractText": ["Induction of premature senescence represents a novel functional strategy to curb the uncontrolled proliferation of malignant cancer cells. This study unveils the regiospecific synthesis of novel isoxazoline derivatives condensed to ring A of medicinal plant product Withaferin-A. Intriguingly, the cis fused products with \u03b2-oriented hydrogen exhibited excellent cytotoxic activities against proliferating human breast cancer MCF7 and colorectal cancer HCT-116 cells. The most potent derivative W-2b triggered premature senescence along with increase in senescence-associated \u03b2-galactosidase activity, G2/M cell cycle arrest, and induction of senescence-specific marker p21<sup>Waf1/Cip1</sup> at its sub-toxic concentration. W-2b conferred a robust increase in phosphorylation of mammalian checkpoint kinase-2 (Chk2) in cancer cells in a dose-dependent manner. Silencing of endogenous Chk2 by siRNA divulged that the amplification of p21 expression and senescence by W-2b was Chk2-dependent. Chk2 activation (either by ectopic overexpression or through treatment with W-2b) suppressed NM23-H1 signaling axis involved in cancer cell proliferation. Finally, W-2b showed excellent in vivo efficacy with 83.8% inhibition of tumor growth at a dose of 25\u2009mg/kg, b.w. in mouse mammary carcinoma model. Our study claims that W-2b could be a potential candidate to limit aberrant cellular proliferation rendering promising improvement in the treatment regime in cancer patients."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Natural Product Chemistry-Microbes, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Rasool", "ForeName": "Faheem", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Nayak", "ForeName": "Debasis", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Katoch", "ForeName": "Archana", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Faheem", "ForeName": "Mir Mohd", "Initials": "MM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Srinagar, 190005, India."}], "LastName": "Yousuf", "ForeName": "Syed Khalid", "Initials": "SK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India."}, {"Identifier": [], "Affiliation": "Natural Product Chemistry-Microbes, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Hussain", "ForeName": "Nazar", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Product Chemistry-Plants, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Belawal", "ForeName": "Chetan", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Product Chemistry-Plants, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India."}], "LastName": "Satti", "ForeName": "N K", "Initials": "NK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India. agoswami@iiim.ac.in."}, {"Identifier": [], "Affiliation": "Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India. agoswami@iiim.ac.in."}], "LastName": "Goswami", "ForeName": "Anindya", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), New Delhi, India. dmukherjee@iiim.ac.in."}, {"Identifier": [], "Affiliation": "Natural Product Chemistry-Microbes, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India. dmukherjee@iiim.ac.in."}], "LastName": "Mukherjee", "ForeName": "Debaraj", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Isoxazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Withanolides"}, {"RegistryNumber": "EC 2.7.1.11", "NameOfSubstance": "Checkpoint Kinase 2"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "CHEK2 protein, human"}, {"RegistryNumber": "L6DO3QW4K5", "NameOfSubstance": "withaferin A"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cellular Senescence"}, {"QualifierName": ["metabolism"], "DescriptorName": "Checkpoint Kinase 2"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Isoxazoles"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Tumor Cells, Cultured"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Withanolides"}, {"QualifierName": [], "DescriptorName": "Xenograft Model Antitumor Assays"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Hanson JR. Steroids: partial synthesis in medicinal chemistry. Nat. Prod. Rep. 2010;27:887\u2013899. doi: 10.1039/c001262a.", "ArticleIdList": ["10.1039/c001262a", "20424788"]}, {"Citation": "Djerassi C. A Steroid autobiography. Steroids. 1984;43:351\u2013361. doi: 10.1016/0039-128X(84)90010-2.", "ArticleIdList": ["10.1016/0039-128X(84)90010-2", "6395452"]}, {"Citation": "Dua R, Shrivastava S, Sonwane SK, Srivastava SK. Pharmacological significance of synthetic heterocycles scaffold: a review. Adv. Biol. Res. 2011;5:120\u2013144."}, {"Citation": "Singh R, Panda G. An overview of synthetic approaches for heterocyclic steroids. Tetrahedron. 2013;69:2853\u20132884. doi: 10.1016/j.tet.2013.02.018.", "ArticleIdList": ["10.1016/j.tet.2013.02.018"]}, {"Citation": "Frank E, Schneider G. Synthesis of sex hormone-derived modified steroids possessing antiproliferative activity. J. Steroid Biochem. Mol. Biol. 2013;137:301\u2013315. doi: 10.1016/j.jsbmb.2013.02.018.", "ArticleIdList": ["10.1016/j.jsbmb.2013.02.018", "23499871"]}, {"Citation": "Lavie, D., Glotter, E. & Shvo, Y. 1371. Constituents of Withania somnifera Dun. Part IV. The structure of withaferin A. J. Chem. Soc. 7517\u20137531 (1965)."}, {"Citation": "Devi PU, Sharada AC, Solomon FE. In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma. Cancer Lett. 1995;95:189\u2013193. doi: 10.1016/0304-3835(95)03892-Z.", "ArticleIdList": ["10.1016/0304-3835(95)03892-Z", "7656229"]}, {"Citation": "Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003;74:125\u2013132. doi: 10.1016/j.lfs.2003.07.007.", "ArticleIdList": ["10.1016/j.lfs.2003.07.007", "14575818"]}, {"Citation": "Tangallapally RP, et al. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg. Med. Chem. Lett. 2007;17:6638\u20136642. doi: 10.1016/j.bmcl.2007.09.048.", "ArticleIdList": ["10.1016/j.bmcl.2007.09.048", "PMC2140235", "17937983"]}, {"Citation": "J\u00c3ger V, Buss V, Schwab W. Syntheses via isoxazolines III. Diastereoselective synthesis of \u03b3-amino-alcohols with 2 and 3 chiral centres. Tetrahedron Lett. 1978;19:3133\u20133136. doi: 10.1016/S0040-4039(01)94963-9.", "ArticleIdList": ["10.1016/S0040-4039(01)94963-9"]}, {"Citation": "Rodier F, Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011;192:547\u2013556. doi: 10.1083/jcb.201009094.", "ArticleIdList": ["10.1083/jcb.201009094", "PMC3044123", "21321098"]}, {"Citation": "Campisi J, di Fagagna FDA. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007;8:729\u2013740. doi: 10.1038/nrm2233.", "ArticleIdList": ["10.1038/nrm2233", "17667954"]}, {"Citation": "Kong, Y., Cui, H., Ramkumar, C. & Zhang, H. Regulation of senescence in cancer and aging. J. Aging Res. 2011 (2011).", "ArticleIdList": ["PMC3056284", "21423549"]}, {"Citation": "Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin. Cancer Res. 2010;17:401\u2013405. doi: 10.1158/1078-0432.CCR-10-1215.", "ArticleIdList": ["10.1158/1078-0432.CCR-10-1215", "21088254"]}, {"Citation": "Hirao A, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 2002;22:6521\u20136532. doi: 10.1128/MCB.22.18.6521-6532.2002.", "ArticleIdList": ["10.1128/MCB.22.18.6521-6532.2002", "PMC135625", "12192050"]}, {"Citation": "Gire V, Roux P, Wynford-Thomas D, Brondello J-M, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 2004;23:2554\u20132563. doi: 10.1038/sj.emboj.7600259.", "ArticleIdList": ["10.1038/sj.emboj.7600259", "PMC449769", "15192702"]}, {"Citation": "Chen C-R, et al. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 2005;65:6017\u20136021. doi: 10.1158/0008-5472.CAN-05-0677.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-0677", "16024600"]}, {"Citation": "Aliouat-Denis CC-M, et al. p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol. Cancer Res. 2005;3:627\u2013634. doi: 10.1158/1541-7786.MCR-05-0121.", "ArticleIdList": ["10.1158/1541-7786.MCR-05-0121", "16317088"]}, {"Citation": "Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J. Nat. Cancer Inst. 2010;102:1536\u20131546. doi: 10.1093/jnci/djq364.", "ArticleIdList": ["10.1093/jnci/djq364", "PMC2957429", "20858887"]}, {"Citation": "Elmore LW, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 2002;277:35509\u201335515. doi: 10.1074/jbc.M205477200.", "ArticleIdList": ["10.1074/jbc.M205477200", "12101184"]}, {"Citation": "Gothelf KV, Jorgensen KA. Asymmetric 1, 3-dipolar cycloaddition reactions. Chem. Rev. 1998;98:863\u2013910. doi: 10.1021/cr970324e.", "ArticleIdList": ["10.1021/cr970324e", "11848917"]}, {"Citation": "Easton CJ, et al. Reversal of regiochemistry in the synthesis of isoxazoles by nitrile oxide cycloadditions. Tetrahedron Lett. 1994;35:3589\u20133592. doi: 10.1016/S0040-4039(00)73248-5.", "ArticleIdList": ["10.1016/S0040-4039(00)73248-5"]}, {"Citation": "Hahm E-R, et al. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PloS one. 2011;6:e23354. doi: 10.1371/journal.pone.0023354.", "ArticleIdList": ["10.1371/journal.pone.0023354", "PMC3154436", "21853114"]}, {"Citation": "Kim S-H, et al. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Res. Treat. 2016;157:41\u201354. doi: 10.1007/s10549-016-3795-y.", "ArticleIdList": ["10.1007/s10549-016-3795-y", "PMC4867258", "27097807"]}, {"Citation": "Choi BY, Kim B-W. Withaferin-A inhibits colon cancer cell growth by blocking STAT3 transcriptional activity. J. Cancer Prev. 2015;20:185. doi: 10.15430/JCP.2015.20.3.185.", "ArticleIdList": ["10.15430/JCP.2015.20.3.185", "PMC4597807", "26473157"]}, {"Citation": "Suman S, et al. Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget. 2016;7:13854\u201313864. doi: 10.18632/oncotarget.7351.", "ArticleIdList": ["10.18632/oncotarget.7351", "PMC4924683", "26883103"]}, {"Citation": "Chakraborty S, et al. Cristacarpin promotes ER stress-mediated ROS generation leading to premature senescence by activation of p21waf-1. AGE. 2016;38:1\u201314. doi: 10.1007/s11357-016-9922-1.", "ArticleIdList": ["10.1007/s11357-016-9922-1", "PMC5005927", "27246693"]}, {"Citation": "Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Huck JJ, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 2010;8:373\u2013384. doi: 10.1158/1541-7786.MCR-09-0300.", "ArticleIdList": ["10.1158/1541-7786.MCR-09-0300", "20197380"]}, {"Citation": "Macip S, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J. 2002;21:2180\u20132188. doi: 10.1093/emboj/21.9.2180.", "ArticleIdList": ["10.1093/emboj/21.9.2180", "PMC125979", "11980715"]}, {"Citation": "Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957\u20131963.", "ArticleIdList": ["11280752"]}, {"Citation": "Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. International journal of cancer. 2012;130:1715\u20131725. doi: 10.1002/ijc.27316.", "ArticleIdList": ["10.1002/ijc.27316", "PMC3288293", "22025288"]}, {"Citation": "Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nature reviews. Molecular cell biology. 2014;15:482. doi: 10.1038/nrm3823.", "ArticleIdList": ["10.1038/nrm3823", "24954210"]}, {"Citation": "Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature reviews. Drug discovery. 2014;13:217. doi: 10.1038/nrd4236.", "ArticleIdList": ["10.1038/nrd4236", "24577402"]}, {"Citation": "Zilla MK, et al. 4\u2032-Demethyl-deoxypodophyllotoxin glucoside isolated from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells. Chem. Biol. Interact. 2014;224:100\u2013107. doi: 10.1016/j.cbi.2014.09.022.", "ArticleIdList": ["10.1016/j.cbi.2014.09.022", "25446499"]}, {"Citation": "Nayak, D. et al. Inhibition of Twist1-mediated invasion by Chk2 promotes premature senescence in p53-defective cancer cells. Cell Death Differ. (2017).", "ArticleIdList": ["PMC5520175", "28498365"]}, {"Citation": "Caligo MA, et al. NM23 gene expression correlates with cell growth rate and S-phase. Int. J. Cancer. 1995;60:837\u2013842. doi: 10.1002/ijc.2910600619.", "ArticleIdList": ["10.1002/ijc.2910600619", "7896455"]}, {"Citation": "Yousuf SK, et al. Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids. 2011;76:1213\u20131222. doi: 10.1016/j.steroids.2011.05.012.", "ArticleIdList": ["10.1016/j.steroids.2011.05.012", "21669217"]}, {"Citation": "Rah B, et al. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PloS one. 2012;7:e44039. doi: 10.1371/journal.pone.0044039.", "ArticleIdList": ["10.1371/journal.pone.0044039", "PMC3433490", "22962598"]}, {"Citation": "Amin, H. et al. Par-4 dependent modulation of cellular \u03b2-catenin by medicinal plant natural product derivative 3-azido Withaferin A. Mol. Carcinog. (2015).", "ArticleIdList": ["25969134"]}, {"Citation": "Rah B, et al. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. Autophagy. 2015;11:314\u2013331. doi: 10.1080/15548627.2015.1017182.", "ArticleIdList": ["10.1080/15548627.2015.1017182", "PMC4502794", "25803782"]}, {"Citation": "Rasool, R. U. et al. Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E. Sci. Rep. 6 (2016).", "ArticleIdList": ["PMC4700468", "26728896"]}, {"Citation": "Lombardi D, Lacombe ML, Paggi M. G. nm 23: Unraveling its biological function in cell differentiation. J. Cell. Physiol. 2000;182:144\u2013149. doi: 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.0.CO;2-6.", "ArticleIdList": ["10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.0.CO;2-6", "10623877"]}, {"Citation": "Rasool RU, et al. Differential regulation of NM23-H1 under hypoxic and serum starvation conditions in metastatic cancer cells and its implication in EMT. Eur. J. Cell Biol. 2017;96:164\u2013171. doi: 10.1016/j.ejcb.2017.01.008.", "ArticleIdList": ["10.1016/j.ejcb.2017.01.008", "28216015"]}, {"Citation": "Steeg PS, et al. Evidence for a novel gene associated with low tumor metastatic potential. J. Nat. Cancer Inst. 1988;80:200\u2013204. doi: 10.1093/jnci/80.3.200.", "ArticleIdList": ["10.1093/jnci/80.3.200", "3346912"]}, {"Citation": "Tee Y-T, Chen G-D, Lin L-Y, Ko J-L, Wang P-H. Nm23-H1: a metastasis-associated gene. Taiwan J. Obstet. Gynecol. 2006;45:107\u2013113. doi: 10.1016/S1028-4559(09)60206-0.", "ArticleIdList": ["10.1016/S1028-4559(09)60206-0", "17197349"]}, {"Citation": "Caligo MA, et al. NM23 gene expression in human breast carcinomas: loss of correlation with cell proliferation in the advanced phase of tumor progression. Int. J. Cancer. 1997;74:102\u2013111. doi: 10.1002/(SICI)1097-0215(19970220)74:1<102::AID-IJC18>3.0.CO;2-H.", "ArticleIdList": ["10.1002/(SICI)1097-0215(19970220)74:1<102::AID-IJC18>3.0.CO;2-H", "9036878"]}, {"Citation": "Oeckinghaus A, Ghosh S. The NF-kB family of transcription factors and its regulation. Cold Spring Harb. Perspect Biol. 2009;1:a000034. doi: 10.1101/cshperspect.a000034.", "ArticleIdList": ["10.1101/cshperspect.a000034", "PMC2773619", "20066092"]}, {"Citation": "You D-J, et al. A Splicing Variant of NME1 Negatively Regulates NF-B Signaling and Inhibits Cancer Metastasis by Interacting with IKK. J. Biol. Chem. 2014;2014:17709\u201317720. doi: 10.1074/jbc.M114.553552.", "ArticleIdList": ["10.1074/jbc.M114.553552", "PMC4067205", "24811176"]}, {"Citation": "Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462\u20136472. doi: 10.1038/onc.2008.312.", "ArticleIdList": ["10.1038/onc.2008.312", "18955973"]}, {"Citation": "La Rosa F, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol. Cell. Biol. 1994;14:1039\u20131044. doi: 10.1128/MCB.14.2.1039.", "ArticleIdList": ["10.1128/MCB.14.2.1039", "PMC358459", "8289784"]}, {"Citation": "Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999;19:5785\u20135799. doi: 10.1128/MCB.19.8.5785.", "ArticleIdList": ["10.1128/MCB.19.8.5785", "PMC84428", "10409765"]}, {"Citation": "Ray A, James MK, Larochelle SP, Fisher RP, Blain SW. p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol. Cell Biol. 2009;29:986\u2013999. doi: 10.1128/MCB.00898-08.", "ArticleIdList": ["10.1128/MCB.00898-08", "PMC2643810", "19075005"]}, {"Citation": "Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 2009;9:400\u2013414. doi: 10.1038/nrc2657.", "ArticleIdList": ["10.1038/nrc2657", "PMC2722839", "19440234"]}]}], "History": [{"Year": "2017", "Month": "5", "Day": "19"}, {"Year": "2017", "Month": "9", "Day": "19"}, {"Year": "2017", "Month": "10", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "10", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "10", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["29062040", "PMC5653814", "10.1038/s41598-017-13664-x", "10.1038/s41598-017-13664-x"]}}]}